FDA loses power to verify biosimilar drugs are truly swappable
H.R. 5526 — Biosimilar Red Tape Elimination Act · Filed by August Pfluger (R-TX) · 10 cosponsors · Introduced Sep 19, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill eliminates the FDA's requirement that biosimilar drugs (generic versions of complex biologic medicines) prove they are 'interchangeable' with the original drug before being approved. Instead, all biosimilars approved after the bill's enactment are automatically deemed interchangeable 60 days after the law passes, unless an earlier biosimilar still holds an exclusivity period. The bill removes the FDA's discretion to require additional testing to confirm interchangeability and shifts the burden of proof away from manufacturers.
Why we flagged it
The bill's operative mechanism is the repeal of the FDA's interchangeability determination requirement, which is a deregulatory move that streamlines biosimilar approval by eliminating a substantive safety-verification gate. The title 'Red Tape Elimination' frames this as burden-reduction, but the substance is removal of a patient-protection standard.
What the text implies
- Automatic interchangeability status removes FDA's ability to require comparative clinical data proving a biosimilar can safely substitute for the reference product, shifting substitution risk to patients and pharmacists.
- Pharmacists and physicians will no longer have FDA-verified interchangeability determinations to guide substitution decisions; they must rely on biosimilarity alone, which is a lower bar.
The full analysis lists 5 implications of this text.
Who stands to gain
biosimilar manufacturers; generic/follow-on biologic drug companies; pharmaceutical manufacturers seeking faster market entry